CAMP4 Therapeutics Pitch Deck: All 18 Slides + Teardown

CAMP4 Therapeutics' Series B deck is a highly technical, data-driven presentation that successfully secured $100M in 2022. Rather than relying on market size tropes, the company focuses on the scientific validation of its RNA Actuating Platform (RAP). By showcasing in vivo Proof of Concept (PoC) data across multiple indications—specifically Dravet Syndrome and Urea Cycle Disorders—CAMP4 demonstrates that its approach to upregulating gene expression via regulatory RNAs (regRNAs) is both programmable and scalable. The deck leans heavily on biological evidence, including non-human primate data a…

Key takeaways

• The deck identifies a catalog of 1,000+ genetic diseases amenable to gene expression increases as the core market opportunity (Slide 3).
• CAMP4 leverages a proprietary RNA Actuating Platform (RAP) to map regRNAs to 20,000 genes (Slide 3).
• Validation is presented through a matrix showing in vitro and in vivo PoC across seven distinct therapeutic areas (Slide 5).
• The platform workflow is broken down into three clear steps: mapping regRNAs, generating ASO drug leads, and programming new medicines (Slide 9).
• Lead candidate CMP-SCN-001 shows dose-dependent upregulation of SCN1A mRNA in human cell lines (Slide 13).
• Non-human primate data confirms protein upregulation across multiple brain regions, including the temporal cortex and thalamus (Slide 15).
• Safety is highlighted by the absence of adverse clinical or histological findings at doses up to 5 mg (Slide 15).
• The company is backed by a high-tier syndicate including Andreessen Horowitz and Northpond Ventures (Slide 3).

Frequently asked questions

What is the primary therapeutic mechanism CAMP4 is developing?

CAMP4 targets regulatory RNAs (regRNAs), such as Enhancer RNA (eRNA), Promoter RNA (pRNA), and Natural antisense transcripts (NATs). By targeting these regRNAs with antisense oligonucleotides (ASOs), the company can precisely upregulate the expression of specific genes to treat diseases caused by haploinsufficiency or low protein production.

How does CAMP4 validate its platform across different tissues?

Slide 5 provides a validation matrix showing Proof of Concept (PoC) in both brain and liver tissues. They demonstrate in vivo PoC for Dravet Syndrome and Frontotemporal Dementia (brain) as well as Urea Cycle Disorders and OTC Deficiency (liver), proving the platform's versatility across different organ systems.

What specific data is provided for their lead program?

For their lead CNS program (Dravet Syndrome), CAMP4 presents data on CMP-SCN-001. Slide 13 shows dose-dependent mRNA upregulation in patient fibroblasts, and Slide 15 shows SCN1A protein upregulation in non-human primates across eight brain regions, supporting a >25X therapeutic margin.

Who are the key investors mentioned in the deck?

The deck explicitly lists four major backers on Slide 3: 5AM Ventures, Polaris Partners, Andreessen Horowitz (a16z), and Northpond Ventures. This syndicate provided the foundation for the $100M Series B round reported by Business Insider.

What is missing from this version of the pitch deck?

This version of the deck omits a dedicated team slide, detailed financial projections, a specific breakdown of the $100M use of funds, and a competitive landscape analysis. It functions primarily as a scientific and platform validation document rather than a full business plan.

CAMP4 Therapeutics pitch deck: the facts

Company

CAMP4 Therapeutics

Year

2022

Stage

Series B

Slides

18

Sector

Biotech

Outcome

$100M raised

CAMP4 Therapeutics pitch deck PDF

The full CAMP4 Therapeutics deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the CAMP4 Therapeutics pitch deck was used for

This deck is a 18‑slide Series B fundraising presentation used by CAMP4 Therapeutics in 2022 to raise a $100M round.[3][8][12] The company is a Cambridge‑based biotech developing antisense oligonucleotide medicines that increase gene expression by targeting regulatory RNAs, powered by its RNA Actuating Platform (RAP™).[1][3][7][9][10][13][15] The Series B financing was intended to expand CAMP4’s regRNA‑targeting platform and advance its lead programs into the clinic, including initial human trials planned for the year following the raise.[1][3][5][6]

Business model: Biotechnology company developing antisense oligonucleotide (ASO) therapeutics that upregulate gene expression by targeting regulatory RNAs (regRNAs), enabled by its proprietary RNA Actuating Platform (RAP™).

Round

Series B[1][3][5][6][8][12]

Raised

$100 million[1][3][5][6][8][12][14]

Lead investor

Enavate Sciences[1][2][5][8][14]

Investors

Enavate Sciences (lead investor, a portfolio company created by Patient Square Capital).[1][2][5][8][14], 5AM Ventures (existing investor participating in the Series B).[1][8], Polaris Partners (existing investor participating).[1][8], Northpond Ventures (existing investor participating).[1][8], Andreessen Horowitz (existing investor participating).[1][8][14], The Kraft Group (existing investor participating).[1][8], Gaingels (new investor).[1][5][8], A large national managed care organization (undisclosed by name).[1]

Headquarters

Cambridge, Massachusetts, USA[1][3][6][12]

Industry

Biotechnology / RNA therapeutics[1][3][5][13]

Year: 2022[1][3][5][6][8][12]

Total funding: Externally reported funding includes a $45M Series A round (2021) followed by a $100M Series B round in July 2022[2][6][12][14].

Use of funds as presented: To accelerate expansion of CAMP4’s novel regulatory RNA‑targeting RAP™ platform and advance its lead regRNA programs into the clinic, including initiating phase 1 trials and initial human testing.[1][3][5][6][12]

What happened after the CAMP4 Therapeutics deck

Following its 2022 Series B deck, CAMP4 successfully raised $100M and has continued to advance its RNA Actuating Platform and regRNA‑targeting ASO programs toward and into clinical development, while establishing strategic collaborations to further leverage its platform.[1][3][5][6][11][13]

• Closing of a $100M Series B financing on July 20, 2022, led by Enavate Sciences, with participation from existing and ne
• Publicly stated plans to use the Series B proceeds to accelerate expansion of the RAP™ platform and move lead regRNA‑tar
• Subsequent public disclosures describing continued development of RAP™, presentation of preclinical data, and strategic

What the CAMP4 Therapeutics deck got right

• Strong platform narrative with clear mechanistic basis. The deck centers on a proprietary RNA Actuating Platform (RAP™) that systematically maps regulatory RNAs controlling ~20,000 genes and uses sequencing plus machine learning to generate antisense oligonucleotide drug leads, providing a clear, differentiated technological backbone.[3][7][9][10][13][15]
• Compelling articulation of large addressable opportunity. Slide language such as “small increases in gene expression can lead to cures for thousands of diseases,” “regulatory RNAs precisely control the expression of 20,000 genes,” and “1,000+ genetic diseases catalogued” effectively communicates a very large therapeutic and commercial opportunity grounded in specific biological levers.[3][9][10][15]
• Evidence of cross‑modal and cross‑tissue applicability. The deck highlights multiple regRNA modalities (enhancer RNAs, promoter RNAs, natural antisense transcripts) and tissues (brain, liver) with in vivo proof‑of‑concept indications, reinforcing that the platform is versatile across gene classes and organ systems rather than being a single‑asset story.[3][4]
• Clear end‑to‑end discovery and development workflow. The workflow described—map regRNAs, generate ASO drug leads, then program new medicines for specific tissues—presents a repeatable discovery‑to‑drug‑candidate engine, which is attractive to investors looking for scalable platform companies.[3][7][9][10][13][15]
• Demonstrated fundraising success with top‑tier syndicate. The deck is backed by a real outcome: a $100M Series B led by Enavate Sciences with participation from multiple high‑quality investors, which validates that the story, as presented, resonated with sophisticated biotech capital providers.[1][3][5][6][8][12][14]
• Tight linkage between platform mechanism and disease biology. By focusing the narrative on restoring expression from remaining healthy gene copies in haploinsufficiency and related disorders, the deck aligns platform capabilities with a well‑defined class of genetic diseases where modest expression increases are scientifically plausible and potentially clinically meaningful.[3][9][10][11][13]

What could have been stronger

• Limited visibility into concrete efficacy or clinical outcomes in the deck text available. From the OCR text of slides 3, 5 and 9, the deck emphasizes platform potential (thousands of diseases, 20,000 genes, 1,000+ catalogued diseases) but provides no quantified clinical or late‑stage preclinical outcomes, making it hard for an investor to gauge actual efficacy beyond early in vivo proof‑of‑concept data.[3][4]
• Platform validation is described qualitatively rather than with numerical data. The slides reference in vivo proof‑of‑concept across brain and liver tissues and multiple regRNA classes, but the OCR indicates only checkmarks and “planned” labels without associated quantitative metrics (effect size, durability, safety), leaving the robustness of the validation unclear from the deck extract alone.[4]
• Ambitious disease scope with limited visible prioritization in the excerpted slides. The deck’s focus on “small increases in gene expression can lead to cures for thousands of diseases” and “1,000+ genetic diseases catalogued” is ambitious, yet the available text does not delineate a near‑term, prioritized pipeline beyond general brain and liver tissue categories, which could make the execution roadmap hard to assess from the slides we see.[3][4]
• Competitive positioning not clearly articulated in the visible slides. While the platform description mentions machine learning, next‑generation sequencing and antisense oligonucleotides, the OCR text does not spell out a detailed competitive landscape or differentiation versus other ASO or RNA‑modulation platforms, leaving investors to infer uniqueness from high‑level claims.[3][4]

How an investor would read this deck

What draws attention

• Clear articulation of a proprietary platform (RAP™) that maps regulatory RNAs and generates ASO therapeutics aimed at upregulating gene expression in a gene‑specific manner, addressing a large class of haploinsufficiency and partial loss‑of‑function disorders.[3][7][9][10][11][13][15]
• Claims that modest increases in gene expression could potentially treat thousands of genetic diseases, supported by a catalog of more than 1,000 diseases mapped to regRNAs, which signals large addressable opportunity.[3][9][10][15]
• Presentation of in vivo proof‑of‑concept data across multiple tissues (brain, liver) and regRNA targets (eRNA, pRNA, NATs), suggesting cross‑tissue applicability of the platform.[4]
• Use of next‑generation sequencing and machine learning to systematically map regRNAs controlling approximately 20,000 genes, which may create defensible datasets and IP.[3][7][9][10][13][15]
• Strong investor syndicate and sizable $100M Series B led by Enavate Sciences and joined by top‑tier VCs and strategic investors, de‑risking financing and validating the thesis.[1][5][8][12][14]

Risks that stand out

• Scientific and translational risk that modest upregulation of gene expression may not consistently translate into meaningful clinical benefit across the broad range of haploinsufficient and recessive partial loss‑of‑function disorders targeted.[9][10][11][13]
• Platform‑level risk related to off‑target effects and long‑term safety of ASO‑mediated gene upregulation, particularly in sensitive tissues such as the brain and liver, which are central to CAMP4’s focus.[4][7][9][10][13]
• Execution risk in moving multiple programs from platform discovery through IND‑enabling studies and into the clinic, given the ambitious scope (thousands of diseases, 1,000+ catalogued) contrasted with finite resources, even with a $100M Series B.[1][3][5][6][9][10]
• Competitive risk from other RNA‑targeting and ASO companies pursuing haploinsufficiency and gene‑upregulation strategies, potentially eroding differentiation if CAMP4’s regRNA mapping or RAP™‑derived assets are not clearly superior.[7][9][10][11][13]

Questions this deck invites

• What quantitative in vivo data (effect size, duration of upregulation, safety margins) support the platform claims, and across which specific gene targets and disease models? The deck excerpt references in vivo PoC but does not show numbers
• Which specific lead programs were prioritized with the Series B proceeds (e.g., gene targets, indications) and what development milestones (IND, phase 1 start) have been achieved since the deck was used?[1][3][5][6][12]
• How does RAP™ compare technically and clinically to competing ASO and RNA‑modulation platforms in terms of specificity, off‑target risk, delivery challenges (especially to the brain), and manufacturability?[7][9][10][11][13]
• What is CAMP4’s IP position around regRNA mapping and ASO design (patent coverage on specific regRNAs, platform methods), and how sustainable is any data advantage they claim?[7][9][10][13]
• What are the regulatory and safety considerations for chronic upregulation of gene expression via ASOs, especially in CNS indications, and how has CAMP4 addressed these in preclinical toxicology packages?[4][7][9][10][13]

What founders can take from the CAMP4 Therapeutics deck

• A clearly branded and mechanistically defined platform like RAP™—with a tight narrative from regRNA mapping to ASO design and therapeutic application—can anchor a large Series B if supported by coherent science and early in vivo data.[1][3][4][7][9][10][11][13]
• Framing the opportunity in terms of thousands of potential genetic diseases and hundreds or thousands of mapped targets can effectively convey scale, but investors will still expect a focused near‑term pipeline to make the story investable.[3][4][9][10][15]
• Demonstrating cross‑tissue applicability (e.g., brain and liver) and multiple regRNA classes (NATs, eRNAs, promoter RNAs) within the deck helps show that the platform is not limited to a single niche, increasing perceived upside.[3][4]
• Pairing complex mechanistic science (regRNAs, antisense oligonucleotides, machine learning mapping) with simple outcome framing (small increases in gene expression can lead to cures) can make a deep‑tech biotech story accessible to a broader investor audience.[3][9][10][15]
• Securing a strong lead investor with domain expertise (Enavate Sciences / Patient Square) and a syndicate of established biotech VCs and strategic players can serve as a signal that the platform has passed rigorous scientific and commercial scrutiny.[1][5][8][12][14]
• Public alignment between fundraising communications (press release, media coverage) and the deck’s core story—expanding the platform and advancing lead programs to the clinic—helps reinforce credibility and makes external validation easier for future investors.[1][3][5][6][12]

CAMP4 Therapeutics pitch deck: common questions

What does CAMP4 Therapeutics do?

CAMP4 Therapeutics is a biotechnology company based in Cambridge, Massachusetts that develops antisense oligonucleotide (ASO) drugs to upregulate gene expression in genetic diseases by targeting regulatory RNAs (regRNAs), using its proprietary RNA Actuating Platform (RAP™).[1][3][7][9][10][13]

How much did CAMP4 raise in its Series B and who invested?

In July 2022, CAMP4 closed a $100 million Series B financing led by Enavate Sciences, a portfolio company created by Patient Square Capital.[1][5][8][12][14] Existing investors 5AM Ventures, Polaris Partners, Northpond Ventures, Andreessen Horowitz, The Kraft Group and others participated, along with a large national managed care organization, Gaingels, and additional undisclosed investors.[1][5][8][14]

What was the purpose of CAMP4’s 2022 Series B round?

According to the company’s July 20, 2022 announcement and contemporaneous coverage, the $100M Series B was intended to accelerate expansion of CAMP4’s RAP™ platform and advance its lead regRNA programs into the clinic, including taking at least one lead asset into phase 1 trials and moving two programs toward clinical testing.[1][3][5][6][12]

What is CAMP4’s RNA Actuating Platform (RAP™)?

RAP™ (RNA Actuating Platform) is CAMP4’s proprietary platform that maps regulatory RNAs controlling protein‑coding genes and generates ASO candidates that target those regRNAs to increase protein expression, particularly in haploinsufficient and recessive partial loss‑of‑function disorders where modest upregulation can be clinically meaningful.[7][9][10][11][13][15]

How does CAMP4’s platform work to identify new drug candidates?

CAMP4’s public materials and deck excerpts indicate that the platform catalogs regRNAs (including enhancer RNAs, promoter RNAs and natural antisense transcripts) across ~20,000 genes, then uses sequencing and machine learning to map regRNAs, identify sequences for maximum gene upregulation, and design ASO drug candidates for specific tissues such as brain and liver.[3][4][7][9][10][13][15]

Sources

Funding and outcome facts on this page were researched on 2026-08-30 from the pages below.

• CAMP4 Secures $100 Million Series B Financing to ...
• Patient Square's Enavate backs Camp4 in $100M series B, ...
• See CAMP4's 18-Slide Pitch Deck, Raising $100M for Its ...
• CAMP4 Presents First Preclinical Data Demonstrating ... - BioSpace
• Equipped with $100M in new cash, CAMP4 takes trail to ...
• With $100M, Camp4 plans to bring two 'regRNA' drugs to clinical trials - Boston Business Journal
• RAP Platform
• CAMP4 Therapeutics Deal Terms

CAMP4 Therapeutics pitch deck slides

What each slide of the CAMP4 Therapeutics pitch deck says

Slide 3

Small increases in gene expression can lead to cures for thousands of diseases % Regulatory RNAs precisely control the expression of 20,000 genes + Enhancer RNA (eRNA) + Promoter RNA (pPRNA) * Natural antisense transcripts (NATs) AM VENTURES ©) RNA Actuating Platform (RAP™) 1,000+ genetic diseases catalogued maps regRNAs to every gene amenable to increases in to enable modulation expression for therapeutic benefit BACKED BY Programming antisense oligonucleotides to rapidly generate new drug candidates against regRNAs

Slide 5

Platform and mechanism validation evidenced by in vivo PoC data sets CAMP4 Restore expression from remaining healthy gene — Gene specific upregulation by targeting regRNAs Tissue Brain Liver Liver Brain Liver Liver Liver regRNA target NAT eRNA eRNA PRNA pRNA pRNA eRNA and pRNA [ nvito Poc v v v v v v v In vivo PoC 4 v v 4 v planned planned

Slide 6

CAMP4 team - experienced and proven leadership JOSH MANDEL-BREHM KELLY GOLD @ @ CEO & President CFO [ ] [ ) Biogen, Genzyme Biogen, Deutsche Bank = ® ® = DAVID BUMCROT, PHD MICHELLE GATES - cso Chief People Officer 9 Editas, Alnylem Akamai ) © k-] © © = @ @ ANN BARBIER, MD, PHD CALEB MOORE cmo VP Portfolio Strategy & Business Ops ALFICA SEHGAL, PHD 'YUTING LIU, PHD ‘SVP Discovery & Translation Head of Data Sciences Anyiam Agios g STEVEN HOLTZMAN — Chairman JOSH MANDEL-BREHM — CEO, CAMP4 RAVI THADHANI, MD, MPH — Chief © Academic Officer Mass General Brigham - § JORGE CONDE -Andreessen Horowitz AMIR NASHAT, PHD — Polaris Partners 3 RICHARD YOUNG, PHD — Founder, The © @ SHAAN GANDHI, PHD - Nor…

Slide 9

Our platform: RNA Actuating Platform (RAP™) Map regRNAs Next-gen sequencing powered by machine learning to catalog regRNAs controlling 20k genes v MAPPING... Generate ASO drug leads Rapidly identify regRNA sequences for maximum gene upregulation "NARNN v SCREENING.. Program new medicines Design new ASO medicines for safe and effective delivery to specific tissues underlying disease regRNA sequence v SEQUENCING... RNA Actuator °® ®

Slide text above is read directly from the CAMP4 Therapeutics deck PDF embedded on this page.

Related fundraising guides (24)

• Checkstep Pitch Deck Teardown: A 7-Slide Product Showcase for AI Content Moderation
• Halp Pitch Deck Teardown: A 7-Slide Memo Strategy for a $4M Seed Round
• Swipes Pitch Deck Teardown: A Minimalist Approach to Productivity Fundraising
• Brag House Pitch Deck Teardown: Targeting the Casual Collegiate Esports Market
• Factorial Pitch Deck Teardown: A Narrative-Driven Series C Strategy for HR Tech
• Viso Pitch Deck Teardown: A 42-Slide Masterclass in Computer Vision Infrastructure
• Arist Pitch Deck Teardown: The $12M Series A Memo Strategy for Micro-Learning
• Domino Data Lab Pitch Deck Teardown: A Masterclass in Enterprise Social Proof
• HTEC Group Pitch Deck Teardown: Scaling Global Engineering Services via M&A and Talent Density
• Agave Games Pitch Deck Teardown: A $7M Seed Round Built on Mobile Gaming Pedigree
• Clutch Wallet Pitch Deck Teardown: A $800k Pre-Seed Bet on Web3 Inclusivity
• Haystack Oncology Pitch Deck Teardown: A Masterclass in Pedigree-Driven Biotech Fundraising
• Limetree Pitch Deck Teardown: A Case Study in Early-Stage Family Media Preservation
• Bravo Sierra Pitch Deck Teardown: Leveraging Military Community for CPG Scale
• Fictiv Pitch Deck Teardown: A $100M Series E Masterclass in Supply Chain Simplification
• Yuzu Health Pitch Deck Teardown: A Masterclass in Market Education and Infrastructure Replacement
• Assembly Pitch Deck Teardown: A Product-First Series A Narrative Focused on Retention
• ElasticStage Pitch Deck Teardown: Solving the 12-Month Vinyl Supply Chain Bottleneck
• Include Pitch Deck Teardown: Scaling Smart City Infrastructure Through Global Distribution
• Friday Finance Pitch Deck Teardown: A $20M Series A Built on Aggregation and Social Proof
• Code First Girls Pitch Deck Teardown: A Masterclass in B2B Social Impact Scaling
• Heura Pitch Deck Teardown: Dominating the Mediterranean Plant-Based Market
• Orchid Pitch Deck Teardown: A Masterclass in High-Stakes Clinical Validation
• Calico Pitch Deck Teardown: A 6-Slide Masterclass in Supply Chain Simplification

This deck's categories (1)

• Series A & Series B Pitch Deck Examples

Decks from the same year (1)

• 2022 pitch deck examples

Decks with a similar raise (1)

• Pitch decks that raised $50M to $250M

Browse companies alphabetically (1)

• Pitch decks from companies starting with C

Decks in the same category (12)

• MySQL 2003 Series B Pitch Deck Breakdown
• Oscar Health Pitch Deck Breakdown
• LinkedIn 2004 Pitch Deck Breakdown: How Networks Became the Next Big Thing
• DoggyHut Pitch Deck Breakdown: The Perfect Series A Deck For A Company That Does Not Exist
• Monzo Pitch Deck Breakdown: Building the Bank of the Future
• Pendo Series B Pitch Deck Breakdown
• Taster Pitch Deck Breakdown: Scaling Digital Restaurant Brands via a Licensing Model
• Zio Studios Pitch Deck Breakdown: A Transmedia Pivot from Services to IP
• Hadean Pitch Deck Breakdown: Proving Technical Scale Through Enterprise Case Studies
• Now Pitch Deck Breakdown: A $29M Series A Built on Municipal Bond Securitization
• Hangry Pitch Deck Breakdown: Scaling Multi-Brand Virtual Restaurants in Indonesia
• Seedtag Pitch Deck Breakdown: Leveraging the Post-Cookie Era with Contextual AI

More pitch deck teardowns (16)

• CallPage Pitch Deck Teardown: A Masterclass in Minimalist Traction-First Storytelling
• Call the Doc Pitch Deck Teardown: A Hyper-Aggressive Approach to Indian Healthtech Scaling
• CallTree Pro Pitch Deck Teardown: A 2014 Look at Enterprise Incident Management
• Calpian OTC CLPI Pitch Deck Teardown: A Case Study in Cash-to-Digital Arbitrage in India
• Calyoga Pitch Deck Teardown: A Brick-and-Mortar Expansion Play for Boutique Fitness
• CalypsoAI Pitch Deck Teardown: A Masterclass in Government-First Market Validation
• Cambridge GaN Devices Pitch Deck Breakdown: A Masterclass in Deep Tech Credibility
• Camdog Pitch Deck Teardown: A Hardware-Agnostic Play for Video Surveillance as a Service
• CampAssist Pitch Deck Teardown: A Student-Focused Social Platform for the Pakistani Market
• CampusFeed Pitch Deck Teardown: Targeting the $300B High School MCN Market
• Canada Jetlines Pitch Deck Teardown: Navigating a Duopolistic Aviation Market
• Canadian Overseas Petroleum Limited Pitch Deck Teardown: Asset Consolidation and Refinancing
• Canary Technologies Pitch Deck Breakdown: A Masterclass in Vertical SaaS Expansion Strategy
• Cancer Genetics Pitch Deck Teardown: Mapping the Transition from Services to Precision Care
• Candidate.fyi Pitch Deck Teardown: A $1.3M Seed Round Built on the Candidate Experience Gap
• Indifi Pitch Deck Teardown: A Late-Stage Fintech Playbook for MSME Lending in India

Recently published pitch deck teardowns (12)

• Open Forest Protocol Pitch Deck Teardown: A $4.1M Pre-Seed Play for Web3 Carbon Verification
• Opkit Pitch Deck Teardown: A Lean 8-Slide Masterclass in Developer-First Healthtech
• OppZo Pitch Deck Teardown: Leveraging Debt Capital to Scale SMB Government Lending
• Optera Pitch Deck Teardown: A 7-Slide Masterclass in Enterprise Traction and Regulatory Tailwinds
• Orange Slice Pitch Deck Teardown: A 7-Slide Masterclass in Narrative Simplicity
• Organise Pitch Deck Teardown: A Masterclass in Traction-First Social Impact Storytelling
• Origin Pitch Deck Teardown: A $5M Seed Strategy for Human-in-the-Loop Travel Curation
• Opus Pitch Deck Teardown: A $6.8M Seed Masterclass in Deskless Workforce Training
• ORIGYN Foundation Pitch Deck Teardown: A $20M Pre-Series A Masterclass in Trust Architecture
• Oakland Ballers Pitch Deck Teardown: Leveraging Sports Disruption as a Media Platform
• Ovom Pitch Deck Teardown: A Full-Stack Hybrid Approach to AI Fertility Care
• One Point Five Pitch Deck Teardown: An Asset-Light Strategy for Sustainable Packaging

Fundraising library · Pitch deck examples · Investor directory · Founder database